Get the Stockscreener App
1.65
1.23%
0.02
After Hours:
1.57
-0.08
-4.85%
Soligenix Inc stock is traded at $1.65, with a volume of 350.07K.
It is up +1.23% in the last 24 hours and up +21.32% over the past month.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
See More
Previous Close:
$1.63
Open:
$1.63
24h Volume:
350.07K
Relative Volume:
0.33
Market Cap:
$16.64M
Revenue:
$960.60K
Net Income/Loss:
$-7.10M
P/E Ratio:
-0.2183
EPS:
-7.56
Net Cash Flow:
$-8.00M
1W Performance:
+2.48%
1M Performance:
+21.32%
6M Performance:
-10.33%
1Y Performance:
-50.15%
1-Day Range:
$1.5611
$1.695
1-Week Range:
$1.5056
$1.695
52-Week Range:
$1.09
$6.2299
Soligenix Inc Stock (SNGX) Company Profile
Name
Soligenix Inc
Sector
Industry
Phone
609-538-8200
Address
29 EMMONS DRIVE, PRINCETON
Compare SNGX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNGX
Soligenix Inc
|
1.65 | 16.44M | 960.60K | -7.10M | -8.00M | -7.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Soligenix Inc Stock (SNGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-28-20 | Downgrade | Dawson James | Buy → Neutral |
| Jan-31-18 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-14-17 | Reiterated | Maxim Group | Buy |
| Jul-17-17 | Initiated | H.C. Wainwright | Buy |
Soligenix Inc Stock (SNGX) Latest News
Soligenix (NASDAQ: SNGX) Featured in NetworkNewsAudio APR on Urgent Need for Rare Disease Therapies - Digital Journal
Soligenix’s HyBryte Therapy Advances as Rare Disease Treatment Gap Grows - citybuzz
NetworkNewsAudio Announces Audio Press Release (APR) on Final Confirmatory Clinical Study Being Done for Treatment of Rare Disease - The Manila Times
Soligenix (NASDAQ: SNGX) Receives Strong Vote of Confidence from Zacks Report Despite Muted Market Response to Clinical Milestone - Digital Journal
Soligenix (NASDAQ: SNGX) Featured in BioMedWire Editorial on Rare Disease Therapies - Digital Journal
Soligenix Featured in Editorial on Growing Need for Rare Disease Therapies - citybuzz
Soligenix Inc. (NASDAQ: SNGX) Advancing Rare-Disease Therapies Positioned at Pivotal Crossroad - GlobeNewswire
Why Soligenix Inc. (DOA0) stock signals breakout potentialInflation Watch & Fast Exit and Entry Strategy Plans - Newser
How Soligenix Inc. (DOA) stock expands through international marketsStop Loss & Weekly High Return Opportunities - Newser
Is Soligenix Inc. (DOA0) stock cheap vs fundamentalsTrade Volume Report & Risk Adjusted Swing Trade Ideas - Newser
Is Soligenix Inc. stock a buy before product launchesWeekly Trend Summary & Expert Verified Stock Movement Alerts - Newser
Breakthrough Therapies Advance as Rare Disease Burden Intensifies Across Aging Populations - GlobeNewswire
Is Soligenix Inc. (DOA) stock in buy zone after pullback2025 Volume Leaders & Low Drawdown Momentum Trade Ideas - Newser
Cutaneous T-cell Lymphoma Market Expected to Experience Major Growth by 2032, According to DelveInsight | Innate Pharma, Galderma R&D, Kyowa Kirin, Citius Pharma, Soligenix, 4SC AG, oligenix, Ligand - Barchart.com
Soligenix’s HyBryte Development Intersects with National Rare Disease Policy Needs - citybuzz
Soligenix (NASDAQ: SNGX) Featured in BioMedWire Editorial Highlighting HyBryte(TM) and Rare Disease Policy - Digital Journal
Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space - Yahoo Finance
Will Soligenix Inc. (DOA0) stock gain from lower interest ratesBuy Signal & Fast Entry Momentum Alerts - Newser
Is Soligenix Inc. (DOA0) stock attractive for growth fundsGlobal Markets & Smart Money Movement Tracker - Newser
Is Soligenix Inc. (DOA) stock cheap vs fundamentals2025 Price Targets & Long Hold Capital Preservation Tips - Newser
Why Soligenix Inc. (DOA) stock appears on watchlists2025 EndofYear Setup & Low Risk High Reward Ideas - Newser
Why Soligenix Inc. (DOA) stock attracts HNW investorsQuarterly Profit Summary & Expert Verified Movement Alerts - Newser
Will Soligenix Inc. (DOA) stock maintain strong growthWeekly Trade Review & Daily Profit Maximizing Tips - Newser
Soligenix (NASDAQ: SNGX) Reaches Key Enrollment Milestone in Phase 3 Trial with Encouraging Blinded Response Rate - The Globe and Mail
Soligenix Advances HyBryte Treatment for Rare Disease as Aging Population Faces Growing Healthcare Challenge - citybuzz
Is Soligenix Inc a good long term investmentLow Beta Stocks & Free Superior Stock Performance - earlytimes.in
Is Soligenix Inc. (DOA0) stock safe for risk averse investorsJuly 2025 Summary & Trade Opportunity Analysis Reports - Newser
What downside risks could hit Soligenix Inc. (DOA) stockTrade Exit Report & Community Consensus Picks - Newser
Is Soligenix Inc. (DOA) stock good for long term investing2025 Winners & Losers & Long-Term Growth Stock Strategies - Newser
Soligenix Reaches Enrollment Milestone in Phase 3 CTCL Trial with Promising Early Data - citybuzz
Soligenix (NASDAQ: SNGX) Advancing Heat-Stable Vaccine Platform with New Peer-Reviewed Data - Digital Journal
Is Soligenix Inc DOA a good long term investmentInstitutional Buying Trends & Low Entry Investment Growth - earlytimes.in
Soligenix Announces Synthetic Hypericin Successfully Manufactured at Sterling Pharma Solutions (PR Newswire) - Aktiellt
Soligenix Demonstrates Extended Heat Stability in Filovirus Vaccine Platform - citybuzz
Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma (PR Newswire) - Aktiellt
Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators (PR Newswire) - Aktiellt
Take Profit: Is Soligenix Inc. stock cheap at current valuation2025 Dividend Review & Low Risk High Win Rate Picks - moha.gov.vn
Soligenix (NASDAQ: SNGX) Elevates Advisory Network as Rare Disease Strategy Advance - Digital Journal
Soligenix Corporate Update LetterKey Highlights and Upcoming Milestones (PR Newswire) - Aktiellt
Soligenix (NASDAQ: SNGX) Strengthens CTCL Program as DMC Flags No Safety Issues - Digital Journal
Soligenix Appoints Former White House Economist as Strategic Advisor to Advance Rare Disease Treatments - citybuzz
Soligenix Inc. (SNGX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
What insider purchases suggest about Soligenix Inc. (DOA0) stockPortfolio Value Summary & Accurate Intraday Trade Tips - newser.com
Will Soligenix Inc. (DOA) stock see valuation expansionJuly 2025 Momentum & Accurate Technical Buy Alerts - newser.com
Why Soligenix Inc. stock attracts high net worth investorsTrade Entry Summary & Advanced Swing Trade Entry Plans - newser.com
How Soligenix Inc. stock responds to policy changesMarket Trend Review & Accurate Trade Setup Notifications - newser.com
Soligenix Inc Stock (SNGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):